US 12,454,570 B2
Compositions and methods for growth factor modulation
Thomas Schurpf, Cambridge, MA (US); Nagesh K. Mahanthappa, Cambridge, MA (US); and Michelle Straub, Yarmouth, ME (US)
Assigned to Scholar Rock, Inc., Cambridge, MA (US)
Filed by Scholar Rock, Inc., Cambridge, MA (US)
Filed on Oct. 17, 2023, as Appl. No. 18/488,265.
Application 17/196,256 is a division of application No. 16/209,078, filed on Dec. 4, 2018, granted, now 10,981,981, issued on Apr. 20, 2021.
Application 16/209,078 is a division of application No. 15/671,217, filed on Aug. 8, 2017, abandoned.
Application 15/187,278 is a division of application No. 14/795,033, filed on Jul. 9, 2015, granted, now 9,399,676, issued on Jul. 26, 2016.
Application 18/488,265 is a continuation of application No. 17/196,256, filed on Mar. 9, 2021, granted, now 11,827,698.
Application 15/671,217 is a continuation of application No. 15/187,278, filed on Jun. 20, 2016, granted, now 9,758,577, issued on Sep. 12, 2017.
Application 14/795,033 is a continuation of application No. PCT/US2014/036933, filed on May 6, 2014.
Claims priority of provisional application 61/900,438, filed on Nov. 6, 2013.
Claims priority of provisional application 61/823,552, filed on May 15, 2013.
Claims priority of provisional application 61/819,840, filed on May 6, 2013.
Prior Publication US 2024/0368261 A1, Nov. 7, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/22 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); C07K 14/495 (2006.01); C07K 16/00 (2006.01); C07K 16/28 (2006.01); C12N 15/10 (2006.01); A61K 38/00 (2006.01)
CPC C07K 16/22 (2013.01) [A61K 39/001134 (2018.08); A61K 39/3955 (2013.01); C07K 14/495 (2013.01); C07K 16/005 (2013.01); C07K 16/28 (2013.01); C07K 16/2863 (2013.01); C12N 15/1037 (2013.01); A61K 38/00 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/32 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); G01N 2333/495 (2013.01); G01N 2333/71 (2013.01)] 19 Claims
 
1. A method of identifying an antibody, or an antigen-binding fragment thereof, that binds to human proGDF8 and inhibits GDF8 activation, the method comprising the steps of:
(i) immunizing a host with an antigen comprising a recombinant human proGDF8, wherein the proGDF8 comprises a complex comprising a GDF8 prodomain associated with mature GDF8;
(ii) carrying out a binding assay to screen for hybridoma cells that produce an antibody, or an antigen-binding fragment thereof, that binds to human proGDF8;
(iii) purifying the antibody, or the antigen-binding fragment thereof, from step (ii); and,
(iv) carrying out a growth factor activity assay to test the ability of the antibody, or the antigen-binding fragment thereof, to modulate the activity of GDF8,
thereby identifying an antibody, or an antigen-binding fragment thereof, that binds human proGDF8 and inhibits GDF8 activation.